Contracts › 75N95023F00002
75N95023F00002: Efficacy and Safety Evaluation of Lead Gene Therapy Candidate in Neuromuscular Junction (NMJ) Disease Mouse Models and Bioanalytical Assay Methods Development
Awarded to Lovelace Biomedical Research Institute by National Institutes of Health (NIH).
$1.9Mobligated
$4.0Mpotential value
30 June 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N95023F00002 |
|---|---|
| Vehicle | 75N95019D00012 |
| Awardee | Lovelace Biomedical Research Institute |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | NM |
| Period of performance | 29 September 2023 to 30 June 2028 |
| Potential end | 30 June 2028 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record